IPZYF
IP Group Plc·Financial Services
0.81
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.5752W H: $0.81
IPZYF NEWS
proactiveinvestors.co.uk
Mar 30
IP Group launches Australian cleantech fund with clean energy body
IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has launched a new fund with Australia's Clean Energy Finance Corporation (CEFC) to back cleantech companies targeting hard-to-abate industries. The IP Group Climate Catalyst Fund has a target size of up to A$150 million, with IP Group contributing A$30 million and the CEFC A$20 million as cornerstone investors at first close.
proactiveinvestors.co.uk
Mar 17
Here's why IP Group looks undervalued. Three brokers take a deep dive
Analysts at three brokerages maintain 'buy' ratings after strong full-year results IP Group PLC (LSE:IPO), the London-listed investor that commercialises intellectual property from leading universities, reported a 13% rise in net asset value (NAV) per share to 110.4p for the year ended December 2025, driven by a licensing deal tied to Pfizer's $10 billion acquisition of obesity drug developer Metsera. The company's shares rose 11% on Tuesday to 54.7p.
proactiveinvestors.co.uk
Mar 17
IP Group shares jump 9% as Metsera deal drives return to growth
Shares in IP Group PLC (LSE:IPO) rose 9% to 53.5p on Monday after the company reported net asset value per share climbing to 110.4p, with total NAV reaching £975.1 million. The recovery was driven largely by Pfizer's acquisition of Metsera, a biotechnology company developing obesity treatments.
proactiveinvestors.co.uk
Mar 17
IP Group returns to growth as Pfizer deal drives NAV rise
The university spinout investor posted a 13% increase in net asset value per share after Pfizer's acquisition of obesity drug developer Metsera IP Group PLC (LSE:IPO), the London-listed investor in university spinout companies, has reported a return to growth in 2025, with net asset value (NAV) per share rising 13% to 110.4 pence and total NAV reaching £975.1 million. The improvement follows a difficult 2024, when NAV per share fell 15% and the group posted a loss of £207 million.
proactiveinvestors.co.uk
Mar 4
IP Group portfolio company Oxa raises $103 million in Series D backed by National Wealth Fund and Nvidia
IP Group PLC (LSE:IPO), the London-listed science and technology investor, said portfolio company Oxa Autonomy has raised $103 million in the first close of a Series D funding round, backed by the UK's National Wealth Fund and NVentures, the venture capital arm of chip designer Nvidia. IP Group invested £7.5 million from its own balance sheet and a further £19 million through funds it manages on behalf of Australian pension fund Hostplus, giving it a combined beneficial holding of 20.3% in Oxa.
proactiveinvestors.co.uk
Feb 11
IP Group portfolio company Microbiotica reports promising trial results in ulcerative colitis
MB310, a live biotherapeutic developed by Cambridge-based Microbiotica, achieves 63% remission rate in early study IP Group PLC (LSE:IPO), the London-listed investor in science and technology companies, has announced that portfolio company Microbiotica has reported positive results from a Phase 1b trial of its lead microbiome medicine in ulcerative colitis. The trial met its primary and secondary endpoints, with MB310 demonstrating a strong safety profile, robust engraftment of its eight-strain bacterial consortium and statistically significant clinical improvements compared with placebo.
